These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 24614714)

  • 1. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of cellular therapies: the Australian perspective.
    Wall DM; Prince HM
    Cytotherapy; 2003; 5(4):284-8. PubMed ID: 12944233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of cellular therapy in Australia.
    Trickett AE; Wall DM
    Pathology; 2011 Oct; 43(6):627-34. PubMed ID: 21897330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation Policy for Cell and Tissue Therapies in Australia.
    Sturm M
    Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Update on regulatory framework and certification process].
    Legrand D
    Transfus Clin Biol; 2008 Nov; 15(5):193-6. PubMed ID: 18930686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transposition of the Blood Directive into national law--the perspective of Portugal.
    Gonçalves MH; Muon MC; Gonçalves Jd
    Transfus Clin Biol; 2005 Feb; 12(1):18-20. PubMed ID: 15814287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GMP in blood collection and processing.
    Wagstaff W
    Vox Sang; 1998; 74 Suppl 2():513-21. PubMed ID: 9704492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The quest for quality blood banking program in the new millennium the American way.
    Kim DU
    Int J Hematol; 2002 Aug; 76 Suppl 2():258-62. PubMed ID: 12430934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirements for blood and blood components intended for transfusion or for further manufacturing use. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2015 May; 80(99):29841-906. PubMed ID: 26003966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood transfusion in Europe: basic principles for initial and continuous training in transfusion medicine: an approach to an European harmonisation.
    Mueller MM; Seifried E
    Transfus Clin Biol; 2006 Nov; 13(5):282-5; quiz 286-9. PubMed ID: 17196864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current regulatory issues in cell and tissue therapy.
    Burger SR
    Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacteriology laboratories and musculoskeletal tissue banks in Australia.
    Varettas K
    ANZ J Surg; 2012 Nov; 82(11):775-9. PubMed ID: 22882601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Eurocode International Blood Labeling System" enables unique identification of all biological products from human origin in accordance with the European Directive 2004/23/EC.
    Knels R; Mönig HJ; Wittmann G; von Versen R; Pruss A
    Cell Tissue Bank; 2010 Nov; 11(4):345-52. PubMed ID: 20563859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT).
    Warkentin PI;
    Cytotherapy; 2003; 5(4):299-305. PubMed ID: 12944235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The implementation of tissue banking experiences for setting up a cGMP cell manufacturing facility.
    Arjmand B; Emami-Razavi SH; Larijani B; Norouzi-Javidan A; Aghayan HR
    Cell Tissue Bank; 2012 Dec; 13(4):587-96. PubMed ID: 21870140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The applicability of cGMP to cord blood cell banking.
    Zuck TF
    J Hematother; 1996 Apr; 5(2):135-7. PubMed ID: 8723789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.